STOCK TITAN
  1. Home
  2. News
  3. SONN

Sonnet BioTherapeutics Holdings Inc - SONN STOCK NEWS

Welcome to our dedicated news page for Sonnet BioTherapeutics Holdings (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet BioTherapeutics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sonnet BioTherapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sonnet BioTherapeutics Holdings's position in the market.

News
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. (SONN) to present preclinical data and clinical trial design for SON-080 at AACR Annual Meeting 2023. The study focuses on recombinant human Interleukin-6 for CIPN treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences clinical trial
-
News
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) announces positive safety review for SON-080 in Phase 1b trial, clearing the path for Phase 2 in Diabetic Peripheral Neuropathy. The study's Data Safety Monitoring Board confirmed the consistent adverse event profile and tolerability of SON-080 with previous IL-6 candidates, supporting further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
clinical trial
-
News
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Rhea-AI Summary
Sonnet BioTherapeutics (SONN) publishes promising clinical data on SON-1010, a tumor-targeted immunotherapeutic drug, in Frontiers in Immunology. The study demonstrates safety, tolerability, and efficacy in healthy volunteers and melanoma models. The results support the potential of SON-1010 in enhancing immune responses in the tumor microenvironment, with implications for combination therapies. The publication marks a significant milestone for Sonnet's FHAB technology, paving the way for further dose escalation studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
none
News
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. (SONN) raised $4.55 million through a public offering, published preclinical data on SON-1210, and executed an agreement to sell New Jersey state net operating losses for $4.3 million. They completed enrollment in the Phase 1b portion of the SON-080 trial for chemotherapy-induced peripheral neuropathy. The company provided business updates and financial results for the first quarter of fiscal year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
earnings
-
News
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) announced the publication of extensive preclinical data on SON-1210 in Frontiers in Immunology. SON-1210 is a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy. The paper demonstrated robust binding affinity, in vitro activity, and tumor model efficacy. Repeat doses in non-human primates displayed excellent safety and tolerability, supporting the advancement of SON-1210 into future clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.23%
Tags
none
-
News
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced its financial results for the fiscal year ended September 30th, 2023 and provided a business update. The company had a productive year with important achievements across its pipeline, including the successful completion of the Phase 1 SB102 study with SON-1010 in healthy volunteers and initial data reported from the Phase 1 SB101 study in cancer patients. Sonnet also announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab in platinum-resistant ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
earnings
News
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. completes a $4.55 million financing, projecting cash runway into Q3 2024. The company focuses on business development initiatives and expects updates in the next few quarters. The company advances its therapeutic pipeline with the initiation of the SB221 study in platinum-resistant ovarian cancer and expects early safety data from the SON-080 study in CIPN by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. announces the pricing of an underwritten public offering of common stock and investor warrants, with total gross proceeds of approximately $4.55 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.73%
Tags
offering
-
News
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Rhea-AI Summary
Sonnet BioTherapeutics to present interim data from SB101 clinical trial at Connective Tissue Oncology Society Annual Meeting 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
none
News
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Rhea-AI Summary
Sonnet BioTherapeutics announces data from radiolabeling studies validating tumor targeting attributes of FHAB technology. mIL12-FHAB showed 2.5-4.7 times higher tumor accumulation and increased retention compared to mIL-12. FHAB technology enables broader therapeutic window and potential for improved efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
none
Stock SONN logo
Sonnet BioTherapeutics Holdings Inc

Nasdaq:SONN

SONN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SONN Stock Data

6.14M
2.71M
9.22%
3.53%
14.73%
Food Service Contractors
Accommodation and Food Services
Link
US
Princeton

About SONN

sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies